{"groups":[{"description":"SyB L-0501: The administration of SyB L-0501 at 90 mg/m\\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.","id":"FG000","title":"SyB L-0501"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Progression of the primary disease"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"17"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}